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A B S T R A C T
Background: Transcatheter aortic valve implantation (TAVI) is an effective, less invasive treatment alter-
native for symptomatic severe aortic stenosis (AS). Acute kidney injury (AKI) following TAVI is a common 
complication and is associated with worse outcomes. The age, creatinine, ejection fraction (ACEF) score 
is a simple scoring method, including only three parameters: age, creatinine, and ejection fraction (EF). 
The score was well established in predicting AKI after coronary interventions. 
Aims: We aimed to evaluate whether this simple scoring method, ACEF, may predict a development of 
AKI in patients who underwent TAVI.
Methods: A total of 173 consecutive patients with symptomatic severe AS who underwent TAVI were 
included retrospectively. The primary endpoint of the study was the development of AKI. Study pop-
ulation was divided into two groups according to the presence of AKI. The ACEF score was calculated 
with the formula: age/EF + 1 (if baseline creatinine >2 mg/dl).
Results: Twenty-nine patients developed AKI. The median (interquartile range) ACEF score was 
1.36 (1.20–1.58). The ACEF score was found to be an independent predictor of AKI (P <0.001). The ACEF 
score ≥1.36 predicted AKI development with a sensitivity of 96.6% and specificity of 58.8%. Moreover, 
hypertension, hemoglobin levels, contrast volume, and aortic valve area (AVA) were found to be inde-
pendent predictors of AKI.
Conclusions: Our study revealed that the ACEF score was an independent predictor of AKI. A simple 
and objective score might be very useful in predicting AKI development in patients undergoing TAVI.
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INTRODUCTION
Severe aortic stenosis (AS) is a common heart valve disease, 
especially in the elderly population and the most common 
treatment method used in these patients is surgical aortic 
valve replacement (SAVR) [1]. Transcatheter aortic valve 
implantation (TAVI) has emerged as a new and innovative 
approach to the treatment of severe AS [2, 3]. TAVI has 
become an effective, less invasive, and safe alternative 
treatment option for patients with severe AS who are 
not suitable for SAVR or who are considered to be at high 
surgical risk, and in patients with old age and some comor-
bidities [2, 3]. Recently, several trials have reported that TAVI 
can be considered an important alternative to SAVR even in 
patients with low and intermediate surgical risk. A surgical 
replacement and transcatheter aortic valve implantation 
trial focused on intermediate risk patients and revealed that 
TAVI is not inferior to SAVR [4], PARTNER 3 and Evolut Low 
Risk trials investigated the low-risk patients, and presented 
that TAVI is not inferior [5] or is even superior [6] to SAVR in 
terms of clinical outcomes.
Acute kidney injury (AKI) occurs after TAVI due to 
several factors including comorbidities of the patients, 
hemodynamic alterations during the procedure, and 
pre- or periprocedural contrast media usage [3]. Several 
studies investigated the utility of baseline, procedural 
characteristics or risk scores in predicting AKI following 
TAVI. These studies revealed that the development of 
AKI was closely associated with the patients’ poor clinical 
outcome [7–10]. The age, creatinine, ejection fraction 
(ACEF) score is a simple scoring method that includes 
only three parameters and was originally developed to 
predict mortality in patients undergoing elective coronary 
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W H A T ’ S  N E W ?
In this manuscript, we presented that the age, creatinine, ejection fraction (ACEF) score is an independent predictor of acute 
kidney injury (AKI) in patients who underwent transcatheter aortic valve implantation (TAVI). A simple and objective score can 
be very useful in predicting AKI development. To the best of our knowledge, our study is the first that focuses on the relationship 
between the ACEF score and AKI development in TAVI patients.
artery bypass graft surgery [11]. Also, some investigators 
have examined ACEF, predicting mortality and clinical 
outcomes in patients undergoing percutaneous coronary 
intervention (PCI) [12–15]. The ACEF score has been pre-
viously studied for predicting mortality in patients who 
underwent TAVI but has not been fully investigated in 
predicting AKI. In the present study, we aimed to evaluate 
the utility of the ACEF score in predicting AKI in patients 
who underwent TAVI. 
METHODS 
Study population 
This retrospective cohort study enrolled a total of 188 con-
secutive patients with symptomatic severe AS who under-
went TAVI between December 2017 and June 2020 in the 
University Of Health Sciences Istanbul Mehmet Akif Ersoy 
Thoracic And Cardiovascular Surgery Training and Research 
Hospital, Turkey. Data was obtained after a systematic re-
view of the patients’ hospital records. The decision of TAVI 
was rendered with the consensus of a heart team involving 
cardiovascular surgeons, cardiologists, anesthesiologists, 
and pulmonologists. The preoperative risk was assessed 
with the European System for Cardiac Operative Risk Eval-
uation (EuroSCORE) or Society of Thoracic Surgeons (STS) 
risk calculator systems. Symptomatic severe AS patients 
who met transthoracic echocardiographic criteria at rest or 
with a dobutamine stress test in case of left ventricular im-
pairment were included in study. Severe AS was defined as 
mean gradient >40 mm Hg, velocity >4.0 m/s, aortic valve 
area (AVA) <1 cm² or Indexed AVA <0.6 cm²/m². Exclusion 
criteria were the absence of all medical records, already on 
the treatment of dialysis, patients who died during the pro-
cedure or within 72 hours after the procedure. 10 patients 
who were already on the hemodialysis treatment before the 
procedure and 5 patients who died during the procedure 
or in the first 72 hours were excluded from the study, and, 
finally, 173 patients were included in this study. The study 
protocol was approved by the Local Ethics Committee 
and the study conforms to the principles outlined in the 
Declaration of Helsinki.
Procedural details
The TAVI procedures were performed in a sterile environ-
ment in the catheterization laboratory under conscious 
sedation or general anesthesia. A transfemoral or transapi-
cal approach was used during the procedure. After the 
procedures, the patients were taken to the intensive care 
unit and followed up with non-invasive tests (including 
transthoracic echocardiographic, electrocardiography, and 
laboratory tests).
Clinical assessment and procedural complications
Transient ischemic stroke was defined as brief episodes 
of neurological dysfunction resulting from focal cerebral 
ischemia not associated with permanent cerebral infarction 
[16]. Moreover, ischemic stroke was defined as an episode 
of neurological dysfunction caused by focal cerebral, spinal, 
or retinal infarction [17]. These embolic events, the pres-
ence of clinical signs was confirmed by imaging modalities 
(magnetic resonance imaging with or without computed 
tomography angiography). The clinical diagnosis of a tran-
sient ischemic stroke, stroke, and hemorrhage was made 
by a neurologist. Vascular complications were categorized 
according to Valve Academic Research Consortium mod-
ified classification as major and minor vascular complica-
tions. Thoracic aortic dissection, access site-related vascular 
injury (including dissection, stenosis, perforation, rupture, 
arterio-venous fistula, pseudoaneurysm, hematoma 
>5 cm, irreversible nerve injury or compartment syndrome 
requiring >3 red blood cell units transfusion, peripheral 
embolization requiring surgical intervention or amputa-
tion, and left ventricular perforation were considered as 
major complications. Among the vascular complications, 
those not suitable for major complications were defined 
as minor complications.
Clinical histories, physical examinations, cardiovascular 
risk factors, pre-and post-procedural non-invasive labora-
tory studies, catheterization data such as implanted valve 
type and size, contrast volume used in the procedure, and 
procedural complications of the patients were reviewed 
and recorded. Serum creatinine levels (mg/dl) were mea-
sured within 24 hours before the procedure, immediately 
after the procedure, and daily until the patient was dis-
charged. The ACEF score was calculated according to the 
following formula: ACEF = age/left ventricular ejection 
fraction (%) + 1 (if creatinine was >2.0 mg/dl). 
Study endpoint
The primary endpoint of the study was the develop-
ment of AKI. The AKI was defined according to Valve 
Academic Research Consortium-2 standardized endpoint 
definitions as a change in serum creatinine ≤72 hours 
postprocedure [18].
AKI diagnosis was made according to the following 
3 major criteria: 1) increase in serum creatinine ≥1.5 times 
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compared with baseline, or 2) increase of ≥0.3 mg/dl 
(≥26.4 mmol/l), or 3) urine output <0.5 ml/kg/h for >6 h.
Statistical analysis
Data were analyzed using the Statistical Package for the 
Social Sciences, version 24.0 (SPSS Inc., Chicago, Illinois, 
USA). Whether the variables show normal distribution; 
visual (histograms, probability curves) and analytical 
methods (Kolmogorov-Smirnov and Shapiro-Wilk) were 
evaluated. Numerical variables showing normal distri-
bution were mean (standard deviation [SD]), numerical 
variables not showing normal distribution were expressed 
as median (interquartile range), and categorical variables 
as a percentage (%). Numerical variables were evaluated 
using Student t-tests and the Mann-Whitney U-test be-
tween the two groups. The chi-square or Fisher exact test 
were used to comparing categorical variables. Covariates 
including all baseline and procedural characteristics ex-
hibiting significant P-value in the univariable analysis were 
included in a logistic regression analysis to determine the 
predictive factors of the incidence of AKI. Receiver oper-
ating characteristic curve analysis and Youden index (max 
[sensitivity + specificity – 1]) were used to determine the 
ideal ACEF cut-off value for predicting AKI. Throughout the 
present study, a P-value of <0.05 was considered significant.
RESULTS 
We identified a total of 173 patients (mean age [SD]: 
78.2 [7.4] years, male: 64) who underwent TAVI and met 
the inclusion criteria of the study. Patients were divided 
into two groups according to the presence of AKI as AKI 
(+) and AKI (–) groups. Twenty-nine patients were in AKI 
(+) group and 144 patients were in AKI (–) group. Except 
for age, demographic parameters were not significantly 
different between the two groups (P <0.001). However, 
hypertension rate was significantly higher (P = 0.04), and 
glomerular filtration rate was significantly lower in AKI (+) 
group (P <0.001). Also, hemoglobin levels were signifi-
cantly lower in AKI (+) group (P = 0.005). AKI (+) group had 
significantly lower left ventricular EF (LVEF) (P <0.001) and 
higher STS score (P <0.001). The median (IQR) ACEF score 
was 1.36 (1.20–1.58) and AKI (+) group had significantly 
higher ACEF score (AKI [–]: 1.29 [1.15–1.46] vs AKI [+]: 
1.64 [1.44–1.98], P <0.001) (Supplementary material, Figure 
S1). There was no significant difference in terms of mean 
aortic valve gradient; however, AVA was significantly lower 
in AKI (+) group (P = 0.01). Table 1 shows the demographic, 
clinical, echocardiographic, and laboratory characteristics 
of the patients.
There was no difference between the groups in terms 
of the type (balloon or self-expandable) and sizes of the 
implanted valves. The contrast volume used during the pro-
cedure was significantly higher in AKI (+) group (P = 0.001). 
There was no statistically significant difference between 
the two groups in terms of minor vascular complications 
and stroke; however, major vascular complications were 
significantly higher in the AKI (+) group (P = 0.003). AKI 
(+) group had a higher rate of predilation before valve 
implantation (P = 0.002), no significant differences were 
found in terms of postdilatation, access site, and rapid 
ventricular pacing between groups. Procedural information 
is presented in Table 2.
The parameters which were found to be significant in 
univariable analysis were taken into multivariable logistic 
regression analysis to determine independent associates 
AKI. Although age, LVEF, and STS score were found to be 








Age, years, mean (SD) 78.2 (7.4) 77.1 (7.3) 83.5 (5.8) <0.001
Sex (male), n (%) 64 (37.0) 55 (38.2) 9 (31.0) 0.47
Diabetes mellitus, n (%) 58 (33.5) 49 (34.0) 9 (31.0) 0.76
Hypertension, n (%) 89 (51.4) 69 (47.9) 20 (69.0) 0.04
CAD, n (%) 115 (66.5) 96 (66.7) 19 (65.5) 0.91
PAD, n (%) 48 (27.7) 38 (26.4) 10 (34.5) 0.37
PH, n (%) 51 (29.5) 40 (27.8) 11 (37.9) 0.27
COPD, n (%) 78 (45.1) 65 (45.1) 13 (44.8) 0.98
CVE, n (%) 4 (2.3) 2 (1.4) 2 (6.9) 0.13
STS score 7.8 (5.8–9.2) 7.1 (5.3–9.0) 9.7 (7.8–12.0) <0.001
ACEF score, median (IQR) 1.36 (1.20–1.58) 1.29 (1.15–1.46) 1.64 
(1.44–1.98)
<0.001
LVEF, % 60 (55–65) 60 (55–65) 50 (40–58) <0.001
Mean gradient, mm Hg, mean (SD) 48.4 (10.0) 47.8 (9.6) 51.3 (11.5) 0.09
AVA, cm², mean (SD) 0.75 (0.13) 0.76 (0.13) 0.69 (0.14) 0.010
Hemoglobin, g/dl, mean (SD) 11.0 (1.6) 11.2 (1.6) 10.3 (1.4) 0.005
Creatinine, mg/dl, median (IQR) 1.00 (0.83–1.20) 0.98 (0.82–1.15) 1.04 (0.90–1.30) 0.06
GFR, ml/min, mean (SD) 65.9 (18.9) 68.8 (18.5) 51.7 (14.1) <0.001
Data is presented as percentage, mean (SD) or median (IQR). 
Abbreviations: ACEF, age, creatinine, ejection fraction; AKI, acute kidney injury; AVA, aortic valve area; CAD, coronary artery disease; COPD, chronic obstructive 
pulmonary disease; CVE, cerebrovascular event; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; PH, pulmo-
nary hypertension; STS, Society of Thoracic Surgeons
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significant in the univariable analysis, they were not in-
cluded in the multivariable analysis because age and LVEF 
are the components of ACEF score, and the ACEF score 
parameters exists in the STS score. Hypertension (OR, 15.31; 
95% CI, 3.28–71.40; P = 0.001), ACEF score (OR, 22.91; 95% 
CI, 5.10–102.84; P <0.001), hemoglobin levels (OR, 0.39; 
95% CI, 0.24–0.62; P <0.001), contrast volume (OR, 1.016; 
95% CI, 1.007–1.026; P = 0.001), and AVA (OR, 0.009; 95% 
CI, <0.001–0.957; P = 0.048) were found to be independent 
predictors of AKI (Table 3).
Receiver operating characteristic analysis was gener-
ated to detect the optimal cut-off value of the ACEF score 
in predicting AKI (Supplementary material, Figure S2). The 
ACEF score higher than 1.36 predicted AKI with a sensitivity 
of 96.6%, specificity of 58.8%, positive predictive value of 
34.1%, negative predictive value of 98.7%, and accuracy of 
65.6% (area under curve [AUC]: 0.821; 95% CI, 0.752–0.891; 
P <0.001).
DISCUSSION 
In the present study, we evaluated the effect of the ACEF 
score and other traditional AKI risk parameters on AKI de-
velopment in patients who underwent TAVI. Three major 
findings of the current study are: 1) an ACEF score was an 
independent predictor of AKI in TAVI patients; 2) an ACEF 
score ≥1.36 predicted AKI with the sensitivity of 96.6% 
and specificity of 58.8%; 3) hypertension, hemoglobin 
levels, contrast volume, and AVA were also found to be 
independent predictors of AKI following TAVI.
The ACEF score is a very simple scoring system that 
includes only 3 parameters: age, creatinine, and LVEF. Pre-
viously, it was found to be associated with AKI following 
primary PCI [15, 19] and coronary catheterization [20]. 
The ACEF score has previously been studied in patients 
undergoing TAVI, but most of these studies focused on pre-
dicting mortality from the ACEF score [21, 22]. In addition, 
previously, some studies showed the relationship between 
increasing age and AKI development in TAVI patients [23], 
nevertheless, some studies revealed that there was no 
statistically significant relationship between age and AKI 
development [9, 10, 24]. Although low LVEF has previ-
ously been reported to be an important predictor of AKI 
development [23, 24], Pyxaras et al. [25] indicated that low 
LVEF is not associated with the development of AKI after 
TAVI. Moreover, Elhmidi et al. showed that preprocedural 
creatinine level was a predictor of AKI [26]; however, some 








Balloon expandable 86 (49.7) 73 (50.7) 13 (44.8) 0.56
Self-expandable 87 (50.3) 71 (49.3) 16 (55.2) 0.56
Valve size,  median (IQR) 27 (26–29) 27 (26–29) 29 (26–29) 0.72
Contrast volume, ml,  median (IQR) 125 (100–160) 120 (95–154) 150 (130–193) 0.001
Major vascular complication 11 (6.4) 5 (3.5) 6 (20.7) 0.003
Minor vascular complication 38 (22.0) 33 (22.9) 5 (17.2) 0.50
Stroke 8 (4.6) 6 (4.2) 2 (6.9) 0.62
Post-op blood transfusion 40 (23.1) 29 (20.1) 11 (37.9) 0.04
Predilatation 75 (43.4) 55 (38.2) 20 (69.0) 0.002
Postdilatation 48 (27.7) 40 (27.8) 8 (27.6) 0.98
Rapid pacing 139 (80.3) 117 (81.3) 22 (75.9) 0.51
Access site (apical) 6 (3.5) 5 (3.5) 1 (3.4) 1.0
Data are presented as number (percentage) of patients unless otherwise indicated. 
Abbreviations: see Table 1
Table 3. Univariable and multivariable analysis for detecting the predictors of acute kidney injury following transcatheter aortic valve  
implantation
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Age, 1.140 (1.068–1.218) <0.001
Hypertension 5.217 (1.886–14.432) 0.001 15.310 (3.283–71.398) 0.001
Creatinine 2.745 (0.843–8.942) 0.09
STS 1.316 (1.153–1.503) <0.001
LVEF 0.927 (0.893–0.962) <0.001
ACEF score 7.142 (2.648–19.264) <0.001 22.911 (5.104–102.84) <0.001
AVA 0.018 (0.001–0.413) 0.01 0.009 (<0.001–0.957) 0.048
Hemoglobin 0.560 (0.491–0.889) 0.006 0.388 (0.242–0.622) <0.001
Contrast volume 1.006 (1.000–1.012) 0.04 1.016 (1.007–1.026) 0.001
Predilatasyon 3.596 (1.529–8.460) 0.003 2.373 (0.787–7.633) 0.15
Abbreviations: see Table 1
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investigators revealed no relation between creatinine levels 
and AKI development [25]. In our study, we found that age 
and LVEF were associated with AKI in TAVI patients, whereas 
creatinine level was not associated with the development 
of AKI. Based on the results of previous studies and our 
study, the effects of these three parameters on AKI devel-
opment after TAVI are still controversial. The combination 
of multiple parameters increases the accuracy of risk 
models; however, including too many parameters will be 
difficult in daily clinical use. The main benefit of the ACEF 
score is its easy accessibility, three parameters, and simple 
calculability. Our study showed that the ACEF score was an 
independent predictor of AKI in patients undergoing TAVI. 
In the current literature, several studies were reported on 
the short and long-term mortality after TAVI procedure 
or comparison of the ACEF score with the other scores. In 
addition to our research, only Arai et al. [27] investigated the 
development of AKI in this patient population. However, 
they investigated the development of AKI with a modified 
ACEF score, which included creatinine clearance instead of 
creatinine. They also found that the modified ACEF score is 
an independent predictor of AKI. Gender, age, weight, and 
creatinine values are used in the calculation of creatinine 
clearance. Creatinine clearance is a better predictor of AKI 
when compared to serum creatinine in the patients who 
underwent coronary artery bypass graft surgery [28, 29] 
and the modified ACEF score has been reported to increase 
the accuracy of the original ACEF score among PCI patients 
[30–32]. However, there is no study comparing modified 
ACEF and original ACEF in TAVI patients. In our study, we 
can comment that both original and modified ACEF scores 
predict AKI in patients undergoing TAVI. To the best of our 
knowledge, there is no study which focuses fully on the role 
of ACEF score in predicting AKI in TAVI patients.
The relationship between contrast volume and AKI 
development is also controversial. Previously, Barbash et 
al. reported that there was no statistical difference in the 
contrast volume used during the procedure between the 
groups with and without AKI (117 ± 88 ml vs 98 ± 46 ml, 
P = 0.13) [26]. In another study, it was shown that there was 
no statistical difference between AKI stages and contrast 
volume (103.84 ± 58.53 ml vs 122.61 ± 96.79 ml, P = 0.78) 
[33]. In 2012, Madershahian et al. [34] evaluated the risk 
of AKI after TAVI and reported a significantly increased risk 
of AKI when comparing patients who received a contrast 
volume of >100 ml vs <100 ml of contrast volume. A recent 
metaanalysis by Thongprayoon et al. [35] demonstrated 
no association between high contrast media volume and 
the risk of AKI following TAVI. Hence, the dose of contrast 
media may not play a significant role in the pathogenesis 
of TAVI-related AKI. This finding will likely impact the di-
rection of future studies for TAVI-related AKI prevention. 
In contrast to the findings, Yamamoto et al. [24] indicated 
that a relationship between contrast volume increment and 
high prevalence of AKI. Although contrast volume was not 
identified as an independent predictor of AKI after TAVI in 
previous reports [26, 33–35], it is still of utmost importance 
to establish whether contrast volume should be limited 
in TAVI procedures carried out in an elderly and high risk 
cohort [36]. Similar to the findings of Yamamoto et al. [24], 
in the present study, we found that contrast volume was 
an independent predictor of AKI development in TAVI 
patients. In a review article, Legnazzi et al. [37] reported 
how to prevent contrast induced AKI in the patients un-
dergoing PCI in detail. These approaches might be applied 
to the TAVI patients to avoid AKI development, however it 
should be supported with large prospective studies. We 
also found that hypertension was one of the independent 
predictors of AKI, which is consistent with the current 
literature [23, 36].
In the present study, AKI (+) group had significantly low-
er hemoglobin levels, and lower hemoglobin levels were 
found to be the independent predictors of AKI. Previously, 
Nuis et al. [38] revealed that periprocedural anemia was not 
associated with AKI after TAVI procedures. Hence, the rela-
tionship between hemoglobin levels and the development 
of AKI is still controversial. Larger randomized studies are 
needed to confirm the relationship between hemoglobin 
levels and AKI development.
The present study has several limitations. First of all, 
this was a single-center, retrospective study, and included 
a relatively small patient population. Thus, large prospec-
tive cohort studies are needed to fully appreciate and vali-
date our findings. Second, there was no standard pre- and 
post-hydration regimen for patients who underwent TAVI.
In conclusion, our study showed that a simple and 
objective score, ACEF, may predict AKI development in 
patients who underwent TAVI.
Supplementary material
Supplementary material is available at https://journals.
viamedica.pl/kardiologia_polska.
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